Recombinant Mouse Serine/threonine-protein kinase B-raf (Braf), partial

1. Persistent oncogenic Braf signaling is sufficient to induce widespread DNA methylation and colorectal neoplasia. PMID:29235923
2. Results indicate specific and compensatory functions for proto-oncogene B-Raf (BRAF) and proto-oncogene c-RAF (CRAF) and highlight an addiction to RAF signalling in NRAS-driven melanoma. PMID:28497782
3. Authors report that BrafQ241R/+ mice have neonatal feeding difficulties and esophageal dilation. The esophagus tissues from BrafQ241R/+ mice displayed incomplete replacement of smooth muscle with skeletal muscle and decreased contraction. PMID:28973166
4. mosaic expression of BRAF(V600E) in mouse erythro-myeloid progenitors results in clonal expansion of tissue-resident macrophages and a severe late-onset neurodegenerative disorder PMID:28854169
5. CDX2(Null)/BRAF(V600E) expression in adult mouse intestinal epithelium led to serrated morphology tumors (including carcinomas) and BRAF(V600E) potently interacted with CDX2 silencing to alter gene expression. Like human serrated lesions, CDX2(Null)/BRAF(V600E)-mutant epithelium expressed gastric markers. PMID:28072391
6. expression of an endogenous Braf(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF-inactivating mutations are initiating events in lung oncogenesis PMID:28783725
7. TTM reduces copper levels and MAPK signaling, thereby inhibiting BRAF(V600E)-driven melanoma tumor growth. PMID:28986383
8. BRAF and ROKalpha form independent RAF1 complexes in embryonic fibroblasts (MEFs) treated with epidermal growth factor (EGF). PMID:28270557
9. Braf(V600E) expression, coupled with simultaneous p53 ablation, permits bypass of senescence and progression to lung adenocarcinoma. PMID:28745322
10. These results provide support for the role of BRAF(V600E) in metastasis. PMID:27210749
11. Mechanistically, BRAF and RAF1 operate independently to balance MAPK signaling: BRAF promotes ERK activation, while RAF1 dims stress kinase activation. PMID:27431613
12. Mass spectrometry based screening for potential interaction partners revealed that BRAF interacts and phosphorylates PAX3. PMID:27906130
13. Using a conditional allele for Braf(V600E) , a mutation observed in clinical cases of GIST, authors observed that Braf(V600E) activation was sufficient to drive ICC hyperplasia but not GIST tumorigenesis. PMID:28539323
14. This study detected the BrafV637E mutation by whole-exome analysis in 4/4 hepatic tumors induced by neonatal treatment with diethylnitrosamine (DEN) in male B6C3F1 mice. PMID:27253992
15. a critical threshold for inhibition of MAPK signaling is required to optimally restore expression of thyroid differentiation genes in thyroid cells and in mice with BrafV600E-induced thyroid cancer. PMID:27669459
16. A- and B-Raf ablation in chondrocytes does not alter skeletal development, whereas ablation of C-Raf decreases hypertrophic chondrocyte apoptosis and impairs vascularization of the growth plate. However, ablation of C-Raf does not impair phosphate-induced ERK1/2 phosphorylation in vitro, but leads to rickets by decreasing VEGF protein stability. PMID:28073913
17. these contrasting signatures precisely match those proposed to confer bias toward Hras(CAA61CTA) versus Braf(GTG636GAG) mutations in the original tumor sets. Our findings highlight a novel mechanism whereby exposure history acts through strand-biased mutagenesis to specify activation of preferred oncogenes PMID:27207659
18. these results suggest that the activation of 5-HT1D receptors selectively enhanced IA via the Gbetagamma of the Go-protein, PKA, and the sequential B-Raf-dependent p38 MAPK signaling cascade. PMID:27156838
19. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells. PMID:26750638
20. these data confirm the existence of a negative feedback pathway by which BRAF protein stability is regulated by ERK. PMID:26898828
21. coexpression of BRAF(V600E) and KRAS(G12D) in early tumorigenesis leads to negative selection due to oncogene-induced senescence PMID:26028035
22. findings suggest that targeting ErbB-3 receptors could represent an effective therapeutic approach in BRAF-V600E mutant colon cancer PMID:26160848
23. Cotargeting is the treatment for mutant RAF/MEK/ERK and NF-kB pathways to treat mutant BRAF melanomas. PMID:25751672
24. The CM cell lines, as well as the tumor xenografts and their metastases, were positive for the melanoma markers HMB-45, S100B, and MART-1. Two cell lines and their corresponding xenografts carried a BRAF mutation, the third showed an NRAS mutation. PMID:25722211
25. New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardiofaciocutaneous syndrome. PMID:25035421
26. Results demonstrate that BRAF activates Usp5 to suppress cell cycle checkpoint control and apoptosis by blocking p53 and FAS induction. PMID:24980819
27. The implantation of genetically defined murine BRAF-mutated thyroid cancer cell lines into syngeneic mice results in rapid and synchronous tumor formation. PMID:24295207
28. early activation of the RAF signaling pathway in the ectoderm has effects on specific steps of epidermal differentiation. PMID:25202828
29. The study characterizes a mouse model of melanogenesis where simultaneous Cdkn2a and Lkb1 inactivation in Braf(V600E) melanocytes results in activation of both mTORC1 and mTORC2/Akt, inducing rapid melanoma formation in mice. PMID:25584893
30. The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. PMID:24901049
31. Overexpression of BRAF(V600E) in normal thyroid epithelial (H tori) cells also reduced the effects of Dkk-1 on cell survival. PMID:24848709
32. Inhibition of BRAF induces metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. PMID:24667377
33. MYC inactivation restores BRAF(V600E)-induced senescence in lung tumors in mice. PMID:24934810
34. these data indicate that B-RAF is an important factor in oncogenic C-RAF-mediated tumorigenesis. PMID:25096573
35. Braf(V600E)-driven tumors become addicted to autophagy as a means to preserve mitochondrial function and glutamine metabolism PMID:24362353
36. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors PMID:24345644
37. in mice, mutant Trp53 accelerated BRAF(V600E)-driven melanomagenesis--and TP53 mutations are linked to evidence of UVR-induced DNA damage in human melanoma PMID:24919155
38. results provide evidence that constitutively activated BRAF(V600E) drives aberrant proliferation of monocyte-lineage cells. PMID:24152792
39. Cell-intrinsic RAF signaling is a crucial pathway promoting developmental and regenerative axon growth in the peripheral and central nervous systems. PMID:24733831
40. p53 constrains progression from papillary thyroid cancer to anaplastic thyroid carcinoma in a Braf-mutant mouse. PMID:24711431
41. decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu binding, decreased BRAF(V600E)-driven signalling and tumorigenesis in mice and human cell settings PMID:24717435
42. constitutive BRAF pathway activation in BRAF(Nav1.8) mice results in ectopic and enhanced expression of itch-sensing genes, including gastrin-releasing peptide and MAS-related GPCR member A3, in nociceptors expressing TRPV1 PMID:24216512
43. LKB1 haploinsufficiency as a risk factor for tumor progression of BRAF(V600E) mutated lung adenomas in human cancer patients PMID:23825589
44. EGF, which signals through CRAF, and an activated BRAF mutant also activate PKC and stimulate cell migration through up-regulating RFFL expression. PMID:24114843
45. BRAF(V600E) and ARF deletion synergize to inhibit nucleotide excision repair by epigenetically repressing XPC. PMID:23650282
46. These results suggest that BRAF(V600E) does not appear to induce papillary thyroid carcinomas-like lesions when expressed in a fraction of thyroid cells postnatally under normal TSH concentrations. PMID:23970782
47. The loss of B-Raf significantly reduces MAPK activation in wild type MEFs. PMID:23416466
48. ERK1/2 activation in response to CRH is biphasic, involving a first cAMP- and B-Raf-dependent early phase and a second phase that critically depends on CRHR1 internalization and beta-arrestin2. PMID:23371389
49. role in survival of double-positive thymocytes and in functional activity of single-positive T cells in the periphery PMID:23334952
50. in the absence of BRaf all neuronal cellular structures develop, but neuronal circuits in the cerebellum and hippocampus are partially disturbed besides impaired neuronal generation in both structures. PMID:23505473

Show More

Hide All

UNIGENE: Mm.245513

KEGG: mmu:109880

STRING: 10090.ENSMUSP00000002487